今年上半年，港股"股王"老铺黄金（06181）股价一度触及高点1015港元，截至6月25日收盘，该股年内涨幅近270%，上市以来累计飙升超倍，成为资 本市场的现象级案例。市场普遍关注的是，同样聚焦高端黄金产品、且渠道下沉能力更胜一筹的周六福（06168），能否复制老铺黄金的估值神话？ 根据智通财经APP了解，周六福暗盘平开高走，涨幅曾高达15.21%，收涨12.92%，报27.1港元，成交额1.55亿港元，总市值115.32亿港元。每手100股， 不计手续费，每手赚310港元。 594倍超额认购备受资金追捧 触发套路回拨难挡"入通"势头？ 公开资料显示，周六福此次IPO计划全球发售4680.8万股（占全球发售完成后11%，另有15%发售量调整权），其中香港发售468.08万股，国际发售 4212.72万股，另有15%超额配股权，发售价为每股24.00港元，每手100股，预计募资总额11.23亿港元，IPO市值约为102.13亿港元。本次IPO保荐人为中 金公司和中信建投国际。 在本次IPO发行中，周六福总计引入8名基石投资者，累计认购约5.73亿港元——其中，深圳罗湖国资认购2亿人民币、永诚资本认购1.1亿港 ...

多重利好共振，港股吸引力持续提升 2025 年，港股市场展现出超预期的韧性，特别是在宏观经济不确定性逐步缓解的背景下，南向资金的持续流入成为 港股上行的关键动力。截至今年 6 月 19 日，南向资金累计净买入港股的金额已突破 6960.41 亿港元，相当于 2024 年 全年南向资金净买入额的 86.16%。根据近五年数据，南向资金的流入逐年上升，尤其在 2024 年和 2025 年，资金流 入的同比增速分别达到了 172.27%和 98.87%。这一增长趋势反映了全球投资者对港股的信心不断增强，同时也表明 港股市场具备较强的吸引力。除南向资金外，港股的估值在全球股市中表现出低估优势。截至 2025 年 6 月 19 日，恒 生综合指数的市盈率为 11.3 倍，显著低于标普 500 和中证全指。这种低估值使得港股的投资性价比愈发突出，成为 全球投资者关注的重点。此外，随着全球经济的不确定性逐步缓解，资金流动趋向于从低收益的固定收益资产流向 高回报的风险资产。美联储预计在 2025 年下半年可能会启动降息周期，合并美元走弱趋势，将进一步推动资本流向 包括港股在内的市场，为港股提供了有利的外部环境。综合来看，港股 ...

Core Viewpoint - The rising public awareness of autoimmune diseases, particularly ankylosing spondylitis, has led to increased interest in the pharmaceutical company Ganzhou Hemei Pharmaceutical Co., Ltd. as it seeks to go public with its core drug Mufemilast targeting psoriasis and ankylosing spondylitis [1][6]. Company Overview - Ganzhou Hemei Pharmaceutical is preparing for an IPO under the Hong Kong Stock Exchange's 18A biotechnology rules, focusing on high investment and potential returns typical of biopharmaceutical companies [2]. - The company has not yet generated revenue and relies heavily on government subsidies and continuous financing to sustain operations [2][11]. Product Pipeline - The company has seven clinical-stage small molecule candidates aimed at addressing unmet medical needs in autoimmune diseases and oncology [2]. - Mufemilast is a dual-action PDE4 inhibitor that has entered the NDA priority review process, targeting multiple indications including psoriasis and ankylosing spondylitis [2][3]. Market Potential - The market for psoriasis drugs in China has seen rapid growth, with a compound annual growth rate (CAGR) of 30.4% from 2019 to 2023, reaching a market size of 13.9 billion yuan in 2023, projected to soar to 89.4 billion yuan by 2032 [3]. - The autoimmune disease drug market in China has expanded from $2.5 billion in 2019 to $4 billion in 2023, with expectations to reach $26.3 billion by 2032, reflecting a CAGR of 23.3% [6]. Competitive Landscape - The competitive environment for Mufemilast is intense, with existing competitors having undergone significant price reductions due to national procurement policies, with price drops exceeding 93% for some products [5]. - There are currently five approved small molecule targeted therapies for psoriasis in China, with 37 more in clinical development, indicating a crowded market for Mufemilast [5][8]. Financial Status - The company reported significant losses of 156 million yuan in 2023 and 123 million yuan in 2024, with minimal other income [11]. - The company has undergone multiple rounds of financing since 2021, raising over 500 million yuan to support its operations, with a post-investment valuation of 3.9 billion yuan [11]. Leadership - The founder and chairman, Zhang Hesheng, has over 20 years of experience in biopharmaceuticals and holds a significant voting power in the company [12].

Core Viewpoint - The introduction of 5 billion yuan in strategic investments by Seres Group's subsidiary, Seres Automotive, aims to strengthen its capital structure and support its ambitious production goals, despite facing competitive pressures in the automotive market [2][3][5]. Group 1: Investment and Financial Structure - Seres Automotive has successfully raised 5 billion yuan from nine strategic investors, increasing its registered capital to 10.637 billion yuan [2]. - The capital increase is intended to enhance Seres Automotive's capital strength and reduce its debt-to-asset ratio, which stood at 76.83% as of Q1 2025, above the industry average [3]. - The company reported a net cash outflow of 7.6 billion yuan in Q1 2025, indicating significant short-term repayment pressure, which the new funding could alleviate [3]. Group 2: Production Capacity and Goals - The capital injection is also aimed at expanding production capacity, with Seres Group targeting an annual production and sales volume of one million units for its "Wenjie" brand within three years [3][4]. - The company has three factories with a total designed annual capacity of 600,000 vehicles, and the utilization rate of its facilities reached 98.93% in the first nine months of 2024 [3]. Group 3: Strategic Partnerships and Market Position - The new investors include major state-owned banks and industry funds, which are expected to enhance supply chain collaboration and resource integration for Seres Automotive [4]. - The partnership with state-owned entities may improve the valuation of Seres' upcoming Hong Kong IPO, which was initiated on April 28, 2024 [4]. - Despite the positive developments, Seres Group faced a 22.92% year-on-year decline in sales, totaling 108,800 vehicles from January to May 2025, and its R&D expenditure as a percentage of revenue fell to 3.2%, below the industry average of 5%-8% [5].

以下文章来源于大胡子财研社 ，作者湾区区长 大胡子财研社 . 真人实地调研，专注楼市研究10余年！大胡子教买房为您带来一手消息，助您预判楼市风向，实现资产 稳步增长！ 接下来，香港可能会有一个大动作—— 干预货币，拉升港元的汇率。 而这个举动，可能会导致香港资本市场迎来一波动荡。 从5月份到现在，港股出现了一波上涨，恒生指数从5月初的22600点涨到了本月最高的24300点。 这一波上涨，主要动力 并不在于基本面的改善，而是资金面的刺激 。 简单说，就 是 从5月份开始， 市场上的港币流动性大幅度增加，助推了恒生指数的上涨。 为什么5月份开始，香港的港币流动性会大幅度增加。 主要是因为 港币汇率在5月份触及到了7.75的最高点。 大家要知道的是，香港港元的汇率采用的是 联系汇率 制度，港元币值和美元的币值绑定。 联系汇率下，港元币值只能在7.75-7.85之间波动。 触及7.75，金管局就抛港元买美元促使港元贬值； 触及7.85，金管局就买港元抛美元促使港元升值。 5月初的时候，因为 老 美搞对等关税，美元疯狂贬值，导致港元相对美元快速升值 ，港元汇率一 路升到了7.75，在联系汇率下港元币值触及强币值边际。 ...

Core Viewpoint - The Hong Kong dollar (HKD) has recently experienced significant fluctuations, approaching the "weak side convertibility guarantee" of 7.85, with the Hong Kong Monetary Authority intervening to sell HKD to stabilize the currency [1][3]. Currency Fluctuation and Market Impact - The HKD's rapid movement between the strong and weak side convertibility guarantees has not been seen in the past decade, indicating heightened volatility in the currency market [1]. - The intervention by the Hong Kong Monetary Authority has led to an increase in HKD liquidity, resulting in a significant decline in HKD interest rates, which has widened the interest rate differential between HKD and USD, creating opportunities for carry trades [3][4]. Stock Market Performance - Despite concerns over liquidity in the Hong Kong stock market, the market has shown resilience, particularly in the dividend sector. The Hang Seng Index rose by 8.8% from May to June 24, while the S&P Hong Kong Low Volatility Dividend Index increased by 10% during the same period [3][4]. - Historical analysis shows that during previous periods of HKD weakness (2018-2019 and 2022-2023), the dividend sector outperformed the overall Hang Seng Index, highlighting its defensive characteristics [4][10]. Long-term Investment Value - The S&P Hong Kong Low Volatility Dividend Index has demonstrated strong performance during periods of market volatility, with a 17.2% increase over the past 12 months compared to a mere 2.1% rise in the Hang Seng Index [10]. - The current low interest rate environment, with the 10-year government bond yield dropping from over 2.5% to 1.7%, enhances the long-term investment appeal of Hong Kong dividend stocks, particularly for investors not subject to dividend tax [10][19]. Inflow of Capital - The influx of mainland capital has significantly supported the liquidity of the Hong Kong stock market, with net purchases from southbound funds reaching 676.08 billion HKD this year, nearing the total for the previous year [17][19]. - The financial sector has seen the largest increase in market value from southbound funds, with a rise of 370.1 billion HKD, indicating strong interest in dividend-paying stocks [19]. Future Outlook - The recent HKD fluctuations are viewed as a conflict between global monetary policy divergence and excess liquidity in Hong Kong. Analysts expect that the negative impact on the market from potential HKD tightening will be manageable [23]. - The overall market sentiment is improving due to strong economic fundamentals in China and ongoing inflows of southbound capital, suggesting a favorable environment for the Hong Kong stock market moving forward [23].

Core Viewpoint - Xiangjiang Electric (02619.HK) was listed on the Hong Kong Stock Exchange on June 25, with an offering price of HKD 2.86 and a P/E ratio of 5.21 times. Despite a strong subscription demand with a margin multiple exceeding 671 times, the stock price fell over 11% post-listing, indicating potential risks in the Hong Kong IPO market [1]. Company Overview - Xiangjiang Electric focuses on the research, design, production, and sales of electrical and non-electrical home products, with approximately 80% of its revenue derived from electrical home appliances [2]. Financial Performance - The company reported revenues of approximately RMB 1.10 billion, RMB 1.19 billion, and RMB 1.50 billion for the fiscal years 2022, 2023, and 2024, respectively. The gross profit margins were 20.4%, 24.1%, and 21.9% during the same periods, with net profits of approximately RMB 80 million, RMB 121 million, and RMB 140 million [4]. Product Breakdown - The revenue from electrical home appliances includes: - Heating appliances: RMB 459.01 million (41.8%), RMB 499.10 million (42.0%), RMB 757.88 million (50.5%) - Electric appliances: RMB 317.62 million (29.0%), RMB 321.94 million (27.1%), RMB 315.56 million (21.0%) - Electronic appliances: RMB 122.99 million (11.2%), RMB 111.57 million (9.4%), RMB 115.07 million (7.7%) - Non-electrical home products include garden hoses and cookware, contributing 20% to 21.5% of total revenue during the reporting period [3]. Market Presence - Over 90% of Xiangjiang Electric's revenue comes from overseas markets, with sales to the U.S. accounting for 68.8%, 80.6%, and 76.5% of total revenue in the respective fiscal years [4]. Production Facilities - The company has established seven manufacturing bases in China and is expanding internationally with a new facility in Indonesia expected to start production in Q2 2025, and another planned in Thailand for H2 2025 [4]. Client Base - In the fiscal years 2022, 2023, and 2024, four to five of the company's top clients were U.S. companies. The ongoing U.S.-China trade tensions and increased tariffs on Chinese imports may impact the company's export revenues [5].

Core Viewpoint - The recent "624" rally is reminiscent of last year's "924" event, with Hong Kong's tech index outperforming the Hang Seng Tech index significantly since April 2023 [1][4]. Performance Comparison - Since the "924" rally, the Hong Kong tech index has increased by 49.75%, outperforming the Hang Seng Tech index by nearly 6 percentage points; since the low on April 8, 2023, it has risen by 21.54% [3][4]. - The Hang Seng Tech index has shown a growth of 20.37% since April 8, 2023, and 43.26% since September 24, 2022 [4]. Sector Analysis - The Hong Kong tech index benefits from a larger number of constituent stocks (50) compared to the Hang Seng Tech index (30), which contributes to its superior performance [4]. - The strong performance of innovative pharmaceuticals within the Hong Kong tech index, which accounts for 8.5% of the index, has also contributed to its outperformance [4]. Investment Recommendations - For investors looking to invest in Hong Kong stocks, the Hong Kong tech index should be prioritized over the Hang Seng Tech index [5]. - The Hong Kong Tech 50 ETF (159750) has gained 0.69% recently and is a popular choice among investors, offering T+0 trading convenience [5][6]. ETF Performance - The Hong Kong Tech 50 ETF has increased by 50.15% since the "924" rally and 12.78% since April 8, 2023, with multiple recent highs [6][8]. - The Hong Kong Dividend Low Volatility ETF (520550) has also performed well, with a 17.69% increase since the "924" rally and 19.86% since April 8, 2023, achieving 35 new historical highs this year [6][8].

Group 1 - The core viewpoint of the articles highlights the increasing interest in Hong Kong dividend assets as a defensive investment amid frequent overseas geopolitical disturbances, with significant capital inflow into the Hong Kong Dividend ETF (513530) [1] - The Hong Kong Dividend ETF (513530) has achieved a record high in both shares and scale, with a 34% increase in scale within the month, reaching 1.682 billion shares and 2.682 billion yuan as of June 23, 2025 [1] - Insurance companies have shown a strong enthusiasm for increasing their holdings in Hong Kong bank stocks, with 19 instances of insurance stake increases reported by June 20, 2025, involving 16 companies, of which 13 were Hong Kong stocks and 9 were bank stocks [1] Group 2 - The Hong Kong Dividend ETF (513530) offers a high dividend yield of 7.66% over the past 12 months, significantly higher than mainstream A-share dividend indices such as the CSI Dividend (5.50%) and Shenzhen Dividend (4.47%) [1] - The ETF is the first in the A-share market that allows investment in the Hong Kong Stock Connect high dividend (CNY) index through the QDII model, providing a more favorable tax structure compared to traditional Hong Kong Stock Connect channels [1] - The fund can conduct monthly dividend assessments, potentially allowing for up to 12 distributions per year, enhancing the flexibility of capital management for investors [2]

Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong stock market, particularly the internet sector, driven by undervalued assets and increased IPOs of quality mainland companies [3][4] - The Hong Kong Internet ETF has seen a significant increase in net value, rising by 47.77% over the past year, ranking in the top 4.95% among index equity funds [4] - The ETF's management fee is competitive at 0.50%, and it has the highest tracking precision among comparable funds, with a tracking error of only 0.050% over the past three months [4] Group 2 - The CSI Hong Kong Internet Index consists of 30 companies related to internet businesses, with the top ten stocks accounting for 77.23% of the index [5] - The top weighted stocks include Alibaba-W, Xiaomi Group-W, and Tencent Holdings, with respective weights of 18.49%, 15.72%, and 14.90% [7] - The current price-to-earnings ratio (PE-TTM) of the index is 22.41, indicating it is at a historical low compared to the past three years [4]